203 related articles for article (PubMed ID: 33600473)
1. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Yamada E; Takagi R; Moro H; Sudo K; Kato S
PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
[TBL] [Abstract][Full Text] [Related]
2. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
4. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
6. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
[TBL] [Abstract][Full Text] [Related]
8. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
9. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.
Yagura H; Watanabe D; Kushida H; Tomishima K; Togami H; Hirano A; Takahashi M; Hirota K; Ikuma M; Kasai D; Nishida Y; Yoshino M; Yamazaki K; Uehira T; Shirasaka T
BMC Infect Dis; 2017 Sep; 17(1):622. PubMed ID: 28915895
[TBL] [Abstract][Full Text] [Related]
10. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
12. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
[TBL] [Abstract][Full Text] [Related]
14. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV.
Calcagno A; Moltó J; Borghetti A; Gervasoni C; Milesi M; Valle M; Avataneo V; Alcantarini C; Pla-Junca F; Trunfio M; D'Avolio A; Di Giambenedetto S; Cattaneo D; Di Perri G; Bonora S
Clin Pharmacokinet; 2021 Jan; 60(1):103-109. PubMed ID: 32737820
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
[TBL] [Abstract][Full Text] [Related]
16. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
Lahiri CD; Brown NL; Ryan KJ; Acosta EP; Sheth AN; Mehta CC; Ingersoll J; Ofotokun I
AIDS; 2018 Sep; 32(15):2151-2159. PubMed ID: 30005011
[TBL] [Abstract][Full Text] [Related]
17. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
18. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.
Lee YL; Lin KY; Cheng SH; Lu PL; Wang NC; Ho MW; Yang CJ; Liou BH; Tang HJ; Huang SS; Huang SH; Chen TC; Lin CY; Lin SP; Lee YT; Hung CC;
Int J Antimicrob Agents; 2021 Sep; 58(3):106403. PubMed ID: 34289404
[TBL] [Abstract][Full Text] [Related]
19. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
20. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
